Enavate Sciences GP, LLC

CIK 0001953107 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗

Enavate Sciences GP, LLC reported 7 positions worth $345.4M as of June 30, 2026 (13F filed August 14, 2026). Largest holding: SION (31.6%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$345.4M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

7 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	SION	SIONNA THERAPEUTICS INC	SH	$109.0M	31.56%	2,478,030	—	—
▸ 2	ZBIO	ZENAS BIOPHARMA INC	SH	$99.5M	28.80%	3,919,159	—	—
▸ 3	IMNM	IMMUNOME INC	SH	$76.6M	22.17%	3,613,799	—	—
▸ 4	BBOT	BRIDGEBIO ONCOLOGY THERAPEUT	SH	$20.0M	5.80%	2,626,946	—	—
▸ 5	CMPX	COMPASS THERAPEUTICS INC	SH	$17.1M	4.94%	7,788,150	—	—
▸ 6	UPB	UPSTREAM BIO INC	SH	$17.0M	4.93%	2,459,703	—	—
▸ 7	CAMP	CAMP4 THERAPEUTICS CORP	SH	$6.2M	1.80%	1,425,541	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Enavate Sciences GP, LLC hold as of Q2 2026?

Enavate Sciences GP, LLC reported 7 positions worth $345.4M in its Q2 2026 13F filing. Largest positions: SION (31.6%), ZBIO (28.8%), IMNM (22.2%), BBOT (5.8%) and CMPX (4.9%).

What did Enavate Sciences GP, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Enavate Sciences GP, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.